VIDEO: Company aims to bring ‘clarity to the complexity’ of medical decision-making
Key takeaways:
- Navya aims to provide timely and personalized treatment plans for people with cancer.
- The company participated in the inaugural CancerX Accelerator cohort.
A digital health company aims to provide timely and personalized treatment plans for every person with cancer, as well as their physicians.
Navya — based in Massachusetts — strives to bring “clarity to the complexity” of medical decision-making, according to Naresh Ramarajan, MD, the company’s founder and chief medical officer.
“Cancer treatment options keep getting more complex, with more clinical trials, more options and more molecular-based therapies,” Ramarajan told Healio. “Patients are faced with all of this complexity, and they’re dealing with it with their treating oncologist. We felt this is a place where technology could really bring some improvement to people’s lives.”
Navya aims to use the power of AI and machine learning to retrieve and synthesize a patient’s electronic medical record, match patients to the latest treatment protocols and trials, and create a draft clinical note for physicians so they can vet the recommendations.
Patients receive documentation in straightforward language that helps them understand their diagnosis, what the next line of therapy will entail and what options they may have for clinical trials, Ramarajan said.
“The patient actually leaves the consult with something that can change the course of their treatment,” Ramarajan said.
Navya participated in the inaugural cohort of the CancerX Accelerator, hosted by Moffitt Cancer Center and launched in collaboration with the Office of the National Coordinator for Health Information Technology and the Office of the Assistant Secretary for Health.
The 16 startups in the cohort collaborated with accelerator champions, mentors, federal partners and CancerX members throughout the health care system to test and validate innovative solutions intended to improve the lives of people with cancer.
Healio has been selected as the official media partner of the 2025 CancerX Accelerator cohort.
In this video, Ramarajan shares insights into his company’s mission, how the company benefitted from participating in the CancerX Accelerator and his advice to this year’s cohort.
Join the CancerX community here.
References:
- CancerX. https://cancerx.health. Accessed March 18, 2025.
- Navya. navyanetwork.com Accessed March 18, 2025.
For more information:
Naresh Ramarajan, MD, can be reached on LinkedIn here.
Collapse
Read more about